Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Classifica tra le azioni #32093
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Prezzo delle azioni
$0.21483059
Ultima sincronizzazione: 2024-05-07
Capitalizzazione di mercato
$11.13M
Variazione (1 giorno)
0.34%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Antibe Therapeutics Inc. (ATE)

Categoria

Cronologia dei frazionamenti azionari per Antibe Therapeutics Inc. (ATE)
L’azione Antibe Therapeutics Inc. (simbolo: ATE) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 18, 2026.
Una quota di ATE acquistata prima di Aug 18, 2026 equivale oggi a 0 quote di ATE.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
9 x285
US
9 x162
US
7 x127
IE
2 x4
US
3 x12
US